<DOC>
	<DOCNO>NCT01215851</DOCNO>
	<brief_summary>The trial evaluate extend bactericidal activity 14 consecutive day oral administration TMC207 alone , TMC207 pyrazinamide , TMC207 PA-824 , PA-824 pyrazinamide PA-824 moxifloxacin pyrazinamide , determined rate change log CFU sputum time period Day 0-14 participant smear positive pulmonary tuberculosis ( TB ) . A control group receive standard treatment .</brief_summary>
	<brief_title>Evaluation Early Bactericidal Activity Pulmonary Tuberculosis With ( J-M-Pa-Z ) ( NC-001 )</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<mesh_term>Bedaquiline</mesh_term>
	<mesh_term>Diarylquinolines</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>1 . Provide write , informed consent prior trialrelated procedure include HIV testing . 2 . Male female , age 18 65 year inclusive . 3 . Body weight ( light clothing shoe ) 40 90 kg , inclusive . 4 . Newly diagnose , previously untreated , sputum smearpositive pulmonary TB . 5 . A chest Xray picture opinion Investigator compatible TB . 6 . Sputum positive direct microscopy acidfast bacillus ( least 1+ IUATLD/WHO scale ) . 7 . Ability produce adequate volume sputum estimate spot assessment ( estimate 10 ml overnight production ) . 8 . Females may participate : 1 ) nonchildbearing potential ( bilateral oophorectomy and/or hysterectomy postmenopausal least 12 consecutive month ) , 2 ) use effective birth control method willing continue practice birth control method throughout treatment 3 ) nonheterosexually active , practice sexual abstinence vasectomize partner ( confirm sterile ) . Therefore eligible study woman childbearing potential either : 1 ) use double barrier method prevent pregnancy ( i.e . use condom either diaphragm cervical cap ) 2 ) use hormonal base contraceptive combination barrier contraceptive , 3 ) use intrauterine device combination barrier contraceptive . They must also willing continue contraceptive measure 6 month last dose study medication 6 month discontinuation study medication case premature discontinuation . ( Note : Hormonebased contraception alone may reliable take IMP ; therefore , hormonebased contraceptive alone use female participant prevent pregnancy ) . 9 . Male participant heterosexual intercourse female childbearing potential require use one follow birth control method participation trial 12 week last dose study medication prevent pregnancy : double barrier method include male condom , diaphragm , cervical cap , female condom ; barrier method combine hormonebased contraceptive intrauterine device female partner . The use mention birth control method apply male participant vasectomise bilateral orchidectomy minimally one month prior screening , heterosexually active , practice sexual abstinence female sexual partner bilateral oophorectomy and/or hysterectomy postmenopausal least 12 consecutive month . Exclusion Criteria Medical History 1 . Evidence clinically significant ( judged investigator ) , metabolic , gastrointestinal , cardiovascular , musculoskeletal , ophthalmological , pulmonary , neurological , psychiatric endocrine disease , malignancy , abnormality ( indication study ) . 2 . Poor general condition delay treatment tolerate per discretion Investigator . 3 . A history previous TB . 4 . Clinically significant evidence extrathoracic TB ( miliary TB , abdominal TB , urogenital TB , osteoarthritic TB , TB meningitis ) , judge Investigator . 5 . History allergy IMP related substance , include know allergy fluoroquinolone antibiotic , history tendinopathy associate quinolones suspect hypersensitivity rifamycin antibiotic . 6 . Isoniazidresistant Rifampicinresistant bacteria detect sputum specimen collect within pretreatment period test study laboratory . 7 . Known suspected , current history within past 2 year , alcohol drug abuse , , opinion Investigator , sufficient compromise safety cooperation participant . 8 . HIV infect participant : 1. CD4+ count &lt; 300 cells/µL ; 2. receive antiretroviral therapy medication within last 90 day ; 3. receive oral intravenous antifungal medication within last 90 day ; 4. AIDSdefining opportunistic infection malignancy ( except pulmonary TB ) . 9 . Having participate clinical study investigational agent within 8 week prior trial start . 10 . Significant cardiac arrhythmia require medication . 11 . Participants follow screening : 1 . Marked prolongation QT/QTc interval , e.g. , confirm demonstration QTcF ( Fridericia correction ) QTcB ( Bazett correction ) interval &gt; 450 m screening ; 2 . History additional risk factor Torsade de Pointes , e.g. , heart failure , hypokalemia , family history Long QT Syndrome ; 3 . Use concomitant medication prolong QT/QTc interval ( see exclusion criterion 22 well list disallow medication Section 4.7.2 ) ; 4 . Pathological Q wave ( define &gt; 40ms depth &gt; 0.40.5mV ) ; 5 . ECG evidence ventricular preexcitation ; 6 . ECG evidence complete incomplete leave bundle branch block right bundle branch block ; 7 . ECG evidence second third degree heart block ; 8 . Intraventricular conduction delay QRS duration &gt; 120ms ; 9 . Bradycardia define sinus rate &lt; 50bpm . 12 . Females pregnant , breastfeeding , plan conceive child within 6 month cessation treatment . 13 . Males plan conceive child within twelve week cessation treatment . 14 . History and/or presence ( evidence ) neuropathy epilepsy . 15 . Diabetes Mellitus require insulin . 16 . History lens opacity evidence lens opacity slit lamp ophthalmologic examination . 17 . For male , evidence history clinically significant abnormality reproductive system , include limited following : serum testosterone , luteinizing hormone ( LH ) , and/or folliclestimulating hormone ( FSH ) level outside laboratory reference range . An evaluation result isolate abnormal value ( i.e. , 1 3 hormone abnormal ) may repeat use morning ( ideally , 8am ) serum specimen . If laboratory value repeat specimen outside laboratory reference range , unless result deem clinically significant Investigator consultation Sponsor Medical Monitor , participant exclude . Specific Treatments 18 . Previously receive treatment TMC207 PA824 part clinical trial . 19 . Treatment receive drug active MTB within 3 month prior Visit 1 ( e.g . isoniazid , ethambutol , amikacin , cycloserine , rifabutin , rifampicin , streptomycin , kanamycin , paraaminosalicylic acid , rifapentine , pyrazinamide , thioacetazone , capreomycin , fluoroquinolones , thioamides , metronidazole ) . 20 . Any disease condition use standard TB drug component contraindicate , include limited allergy TB drug , component IMP . 21 . Any disease condition medicinal product list section pertain prohibited medication use . 22 . Concomitant use drug know prolong QTc interval ( include amiodarone , bepridil , chloroquine , chlorpromazine , cisapride , clarithromycin , disopyramide dofetilide , domperidone , droperidol , erythromycin , halofantrine , haloperidol , ibutilide , levomethadyl , mesoridazine , methadone , pentamidine , pimozide , procainamide , quinidine , sotalol , sparfloxacin , thioridazine ) . The exception moxifloxacin one drug evaluate study , extensive ECG monitoring help ensure patient safety . 23 . Use drug substance within 30 day prior dose know strong inhibitor inducer cytochrome P450 enzyme ( quinidine , tyramine , ketoconazole , testosterone , quinine , gestodene , metyrapone , phenelzine , doxorubicin , troleandomycin , cyclobenzaprine , erythromycin , cocaine , furafylline , cimetidine , dextromethorphan ) . Exceptions may make participant receive 3 day less one drug substance , washout period administration IMP equivalent least 5 halflives drug substance . 24 . Use therapeutic agent know alter major organ function ( e.g. , barbiturate , opiate , phenothiazine , cimetidine ) within 30 day prior dose . 25 . Use systemic glucocorticoid within one year prior dose . Based Laboratory Abnormalities 26 . Participants follow toxicity screen define enhanced Division Microbiology Infectious Disease ( DMID ) adult toxicity table ( November 2007 ) : 1. creatinine grade 2 great ( &gt; 1.5 time upper limit normal [ ULN ] ) ; 2. lipase grade 3 great ( &gt; 2.0 x ULN ) ; 3. hemoglobin grade 4 ( &lt; 6.5 g/dL ) ; 4. platelet grade 2 great ( 50x109 cells/L ) ; 5. serum potassium grade 2 great ( &lt; 3.5 mEq/L ) ; 6. aspartate aminotransferase ( AST ) grade 3 ( ≥3.0 x ULN ) exclude ; 7. alanine aminotransferase ( ALT ) grade 3 ( ≥3.0 x ULN ) exclude ; 8. alkaline phosphatase ( ALP ) grade 4 ( &gt; 8.0 x ULN ) exclude , grade 3 ( ≥3.0 x ULN ) must discuss sponsor Medical Monitor ; 9. total bilirubin grade 3 great ( &gt; 2.0 x ULN , &gt; 1.50 x ULN accompany increase liver function test ) exclude , grade 2 ( &gt; 1.50 x ULN , &gt; 1.25 x ULN accompany increase liver function test ) must discuss sponsor Medical Monitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>EBA</keyword>
	<keyword>TMC207</keyword>
	<keyword>pretomanid</keyword>
	<keyword>Early Bactericidal Activity</keyword>
	<keyword>Pulmonary Tuberculosis</keyword>
	<keyword>PA-824</keyword>
	<keyword>bedaquiline</keyword>
	<keyword>pyrazinamide</keyword>
	<keyword>moxifloxacin</keyword>
	<keyword>ethambutol</keyword>
	<keyword>rifafour</keyword>
</DOC>